Results 171 to 180 of about 10,926,215 (298)

Comparative Analysis of Septin Modifiers, Forchlorfenuron and UR214‐9, on Mitochondrial Fragmentation and Lytic Cell Death

open access: yesCytoskeleton, EarlyView.
ABSTRACT Septins are conserved GTP‐binding proteins that play key roles in cell division, mitochondrial dynamics and immune responses. Despite their importance to human health, pharmacological compounds to modify septins remain limited. Forchlorfenuron (FCF) was the first small molecule identified to modify septins, disrupting their organisation and ...
Dominik Brokatzky   +4 more
wiley   +1 more source

Extrapolation Performance of Convolutional Neural Network-Based Combustion Models for Large-Eddy Simulation: Influence of Reynolds Number, Filter Kernel and Filter Size. [PDF]

open access: yesFlow Turbul Combust
Arumapperuma G   +9 more
europepmc   +1 more source

Fourier Mass Lower Bounds for Batchelor‐Regime Passive Scalars

open access: yesCommunications on Pure and Applied Mathematics, EarlyView.
ABSTRACT Batchelor predicted that a passive scalar ψν$\psi ^\nu$ with diffusivity ν$\nu$, advected by a smooth fluid velocity, should typically have Fourier mass distributed as |ψ̂ν|2(k)≈|k|−d$|\widehat{\psi }^\nu |^2(k) \approx |k|^{-d}$ for |k|≪ν−1/2$|k| \ll \nu ^{-1/2}$.
William Cooperman, Keefer Rowan
wiley   +1 more source

Building a Robust Investigator‐Initiated Platform: The I‐CARE Experience

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Investigator‐initiated studies that include information collected by patients are rising, but limited data is available on patient and investigator experience in this setting. The I‐CARE cohort included patients with inflammatory bowel disease (IBD) monthly collecting clinical information in 15 countries for up to 6 years.
Julien Kirchgesner   +906 more
wiley   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland   +48 more
wiley   +1 more source

Prediction of the Limiting Flux and Its Correlation with the Reynolds Number during the Microfiltration of Skim Milk Using an Improved Model. [PDF]

open access: yesFoods, 2020
Astudillo-Castro C   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy